Epitope specificity determines pathogenicity and detectability of anti-platelet-derived growth factor receptor &#945; autoantibodies in systemic sclerosis by Moroncini, Gianluca et al.
08 January 2022
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
Epitope specificity determines pathogenicity and detectability of anti-platelet-derived growth factor receptor 





(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript
This version is available http://hdl.handle.net/2318/1521840 since 2015-07-23T08:30:47Z
 
Epitope specificity determines pathogenicity and detectability of anti-PDGFR 








































Clinica Medica, Ospedali Riuniti Ancona, 60126 Italy.  
3
Dipartimento di Scienze Mediche, Università di Torino, 10126 Italy.  
4
Scuola di Bioscienze e Medicina Veterinaria, Università di Camerino, 62032 Italy.  
5
Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114 USA. 
6
Dipartimento di Medicina molecolare e Biotecnologie mediche, Università Federico II, Napoli, 
80131 Italy. 
 
# These authors contributed equally. 








Full Length  Arthritis & Rheumatology
DOI 10.1002/art.39125
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/art.39125
© 2015 American College of Rheumatology
Received: Jul 17, 2014; Revised: Feb 09, 2015; Accepted: Mar 17, 2015
This article is protected by copyright. All rights reserved.
2 
 
Objective. This study aimed at cloning autoantibodies targeting the PDGF receptor α (PDGFRα) 
from B cells of one patient with Systemic Sclerosis (SSc), to identify the epitopes recognized by 
these autoantibodies and develop novel assays for detection of serum anti-PDGFR autoantibodies. 
Methods. EBV-immortalized B cells were screened for expression of IgG binding to PDGFRα and 
inducing reactive oxygen species (ROS) in fibroblasts. The variable (V) regions of anti-PDGFRα 
IgG were cloned into an IgG expression vector to generate distinct recombinant human monoclonal 
autoantibodies (rHumaab), which were characterized by binding and functional assays. The 
epitopes of anti-PDGFR rHumaab were defined by molecular docking; surface plasmon resonance 
binding assays; screening of a conformational peptide library spanning the PDGFR extracellular 
domains; expression of alanine-scanned PDGFR mutants. Direct or competitive ELISAs were 
established to detect all the anti-PDGFR antibodies or selectively the agonistic ones.  
Results. Three types of anti-PDGFRα rHumaab, with the same VH but distinct VL chains, were 
generated. Non-agonistic VHPAM-V13B8 recognized one linear epitope, whereas agonistic VHPAM-
V16F4 and VHPAM-Vk16F4 recognized two distinct conformational epitopes. Serum anti-
PDGFR antibodies were detected in 66/70 SSc, 63/130 healthy controls (HC), 11/26 Primary 
Raynaud’s Phenomenon (PRP) and 13/29 SLE patients. Serum VHPAM-Vk16F4-like antibodies 
were found in 24/34 SSc, but not in HC, PRP or SLE. Peptides composing the VHPAM-Vk16F4 
epitope inhibited PDGFRα signaling triggered by SSc IgG.  
Conclusion. Agonistic anti-PDGFR autoantibodies are enriched in SSc sera and recognize 
specific conformational epitopes, that can be used to discriminate agonistic from nonagonistic 
antibodies and block PDGFRα signaling in SSc.  
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Systemic sclerosis or scleroderma (SSc) is a clinically heterogeneous disease of the connective 
tissue characterized by vascular, immune/inflammatory and fibrotic manifestations, in which 
oxidative stress is a prominent feature (1, 2). Despite extensive investigations, the key pathogenic 
links between these disease hallmarks remain obscure, which hampers the development of tools for 
early diagnosis, adequate disease monitoring and effective therapies. We have previously reported 
the presence of agonistic anti-Platelet Derived Growth Factor Receptor (PDGFR) autoantibodies 
stimulating reactive oxygen species (ROS) in the serum IgG of 46 SSc patients (3). However, other 
studies (4, 5) failed to detect these stimulatory antibodies in the serum, and found non-stimulatory 
anti-PDGFR antibodies both in SSc and healthy controls (HC) (5) or in patients with Systemic 
Lupus Erythematosus (SLE) (6). Hence, the presence of stimulatory anti-PDGFR autoantibodies in 
SSc remains controversial (7). To address this issue, we generated combinatorial monoclonal 
autoantibodies using immunoglobulin sequences identified in memory B cells of one SSc patient, 
specific for PDGFR, the isoform which better discriminated SSc IgG from HC IgG (3). By these 
reagents, we obtained a novel map of the functional epitopes of PDGFR selectively driving 
oxidative stress and increase of collagen gene expression. Moreover, we assessed the clinical 




Patients and Methods 
Ethics statements 
Use of human material was approved by the Institutional Ethical Committee of Università 
Politecnica delle Marche, Ancona, Italy, and consent was obtained from all subjects participating to 
this study. All assays were performed in blind fashion on coded samples. 
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Screening of immortalized memory B cells  
CD22-positive memory B cells were purified by magnetic selection (Miltenyi Biotech) from 
peripheral blood mononuclear cells (PBMC) of one patient with diffuse SSc (8) with oesophagus 
and lung involvement (code: PAM, female, 47 years old, Rodnan skin score 17, ANA and anti-Scl 
70 positive, anticentromere negative). Cells were immortalized using Epstein-Barr virus (EBV) as 
described (9-11). Three days post-infection, cells were manually counted and seeded (5 cells/well) 
in 96-well plates in the presence of irradiated (30 Gy) allogenic PBMC. After 2 weeks, B cell 
supernatants were screened for the presence of anti-PDGFR antibodies by immunofluorescence 
and flow cytometry using mouse fibroblasts derived from PDGFR-knockout embryos (F-/-) 
transfected with full-length human PDGFR (F) (12) as target cells, as described (3).  
 
Generation of recombinant human monoclonal autoantibodies  
Total RNA was extracted from each anti-PDGFR positive B cell line (~300.000 cells) with 
RNeasy Micro Kit and reverse-transcribed with Omniscript RT Kit (Qiagen). cDNA was amplified 
with PCR primers specific for human rearranged IgG variable (V) and constant (C), heavy (H) and 
light (L) chain genes (13) (Supplementary Table 1). Amplified H and L chain V regions were 
sequenced by TOPO TA Cloning Kit (Invitrogen). The unique VH and the four different VL chain 
sequences amplified in three PAM B cell lines showing PDGFR binding were alternatively paired 
to replace VH and VL chains of antibody b12 (14), generating four distinct human IgG1 constructs. 
VH and VL sequences were fused with the respective leader peptide sequences using a three-step 
overlap extension PCR (15), then independently inserted into the XbaI-SacI and HindIII-EcoRI 
restriction sites of pDR12 vector containing the parental human IgG1 constant chain genes, 
including the Fc sequence. Upon sequencing, the constructs were stably transfected into Chinese 
hamster ovary (CHO) cells with Lipofectamine 2000 (Invitrogen). Expression of recombinant IgG 
in culture supernatant was confirmed by human IgG-specific ELISA. Cell cultures were expanded 
Page 4 of 33
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
5 
 
in bioreactors (CELLine CL-1000, Integra Biosciences) and secreted recombinant human 
monoclonal autoantibodies (rHumaab) were purified from supernatants by Protein A affinity and 
size exclusion chromatography. Purity of rHumaab was checked by SDS-PAGE Coomassie 
Brilliant Blue protein staining.  
 
Immunoprecipitation and Immunoblotting  
Each rHumaab (10 µg/ml) was incubated for 4 hours at 4°C with 100 g of total protein extracts 
from human fibroblasts. The mixture was incubated overnight at 4°C with 20 l of agarose-Protein 
A/G (Santa Cruz), and the immunocomplexes were subjected to SDS-PAGE and immunoblotting as 
described (3).  
 
Functional assays 
Primary human fibroblasts from adult healthy skin (HDF, Life Technologies) were cultured in 
DMEM with 10% FCS for two passages. At sub-confluence, cells were maintained in 0.2% FCS for 
24 hours, before addition of human PDGF-BB (15 ng/ml), TGF- (2 ng/ml) (R&D Systems) or 
rHumaab (10 g/ml). Protein extracts (30 µg) were separated on 4-12% SDS-PAGE under reducing 
conditions and transferred to PVDF membranes. After blocking, membranes were probed with anti-
pAKT (sc-439), anti-pERK (sc-7783), anti-Ha-Ras (sc-520), stripped and re-probed with anti-total 
AKT, ERK1/2 and -actin (Santa Cruz Biotechnologies), followed by HRP-conjugated antibodies. 
To quantify collagen gene transcription, total RNA was extracted (Aurum total RNA mini Kit, Bio-
Rad) from fibroblasts at baseline and after 1 hour stimulation as indicated. The purity of RNA 
templates measured as 260/280 nm ratio (Nanodrop, Thermo Scientific) was in the 1.8-2.1 range. 
RNA (1 g) was reverse transcribed with iScript cDNA synthesis Kit (Bio-Rad). Human Col1A1 
and Col1A2 genes were measured by real-time PCR with iQ SYBR Green Supermix and iCycler 
(Bio-Rad). Primers: HuCol1A1 fw: 5'-AGGGCCAAGACGAAGACATC-3'; HuCol1A1 rev: 5'-
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AGATCACGTCATCGCACAACA-3'; HuCol1A2 fw: 5'-AGGTCAAACAGGAGCCCGTGGG-3'; 
HuCol1A2 rev: 5'-GCACCTGGGAAGCCTGGAGGG-3'; HuGAPDH fw: 5'-
TGCACCACCAACTGCTTAGC-3'; HuGAPDH rev: 5'-GGCATGGACTGTGGTCATGAG-3'; 
Hu18SrRNA fw: 5'-TCCCCATGAACGAGGAATTC-3'; Hu18SrRNA rev: 5'-
GTGTACAAAGGGCAGGGACTT-3'. PCR conditions: 95°C for 3 minutes, then 95°C for 15 
seconds, 58°C for 60 seconds (45 cycles).  
The ROS bioassay (fluorimetric determination of intracellular ROS generated by adherent 
fibroblasts) was performed as described (16). 
 
Homology modeling and molecular docking  
Homology modeling to predict the unknown three-dimensional structures of human PDGFR and 
rHumaab Fab monovalent fragments from their amino-acid sequences was performed using Swiss-
Model server (17). Swiss-Pdb Viewer software was used to create project files submitted to the 
server with default parameters settings (BLAST search P < 0.00001 and global degree of sequence 
identity SIM > 25%). PDGFR query sequences were obtained from UniProt Knowledgebase 
(http://beta.uniprot.org/). Rigid protein-protein molecular docking between homology-modeled 
monomeric PDGF-BB (pdb-ID: 1PDG) (18), rHumaab Fabs, and monomeric PDGFR was 
performed uploading the pdb files on ClusPro 2.0 server (19) and setting DOT 1.0 as docking 
program, a clustering radius of 5Å, electrostatic hits of 1500 and 30 final resulting structures (data 
available upon request). 
 
Generation and screening of PDGFR peptide library 
Eighty overlapping 15-oligomer synthetic peptides spanning the first three N-terminal, extracellular 
Ig-like domains of PDGFR were flanked by either glycines or cysteines (Cys). Glycine-flanked 
peptides were left in linear conformation, whereas Cys-flanked peptides were imposed on a trivalent 
Page 6 of 33
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
7 
 
(T3) chemical scaffold [containing three PhCH2Br (1,3,5-tribromomesitylene, T3) groups reacting 
1:1 with the three Cys in the peptides, with the sequence: Cys-15-oligomer-Cys-15-oligomer-Cys] 
with spatially defined conformations to mimic a looped conformation. By virtue of this technology 
(Chemically LInked Peptides on Scaffolds, CLIPS, Pepscan Therapeutics BV) (20, 21), the eighty 
15-oligomer segments were all combined with each other to obtain all the possible combinations of 
Cys-15-oligomer-Cys-15-oligomer-Cys bi-cyclical peptides (total T3-CLIPS 30-oligomer peptides 
= 6.400). The T3-CLIPS topology allows the peptides to have either a two looped folding or a loop 
plus partial sheet folding. The combinatory peptides were immobilized onto 455-well plates and 
binding of rHumaab and PDGF-BB was tested by PEPSCAN-based ELISA. 
 
Soluble peptides 
Three peptides were synthesized (Pepscan Therapeutics BV) and numbered from 1 to 3 following 
the amino acid sequence of human extracellular PDGFR from the N- to the C-terminus. Peptide 1: 
ac-VIVEDDDSAIIPCRTTD-conh2; peptide 2: ac-VVPASYDSRQGFNGTFTVGPYICE-conh2; 
peptide 3: ac-CAARQATREVKEMKKVT-conh2. Scrambled peptide 2: ac-
IASGCGTFTRVVFEQPNSPYYDGV-conh2. HPLC purity was > 95%. 
In binding-competition experiments, VHPAM-V16F4 (10 g/ml), (molar ratio peptide: rHumaab = 
100:1) or a pool of IgG from six SSc patients or HC (200 µg/ml) were incubated in solution with 
single peptides for 1 hour at 37°C, then used to stimulate fibroblasts. 
 
PDGFR mutagenesis and expression of PDGFR mutants in F-/- 
Five different sets of Alanine mutations were introduced into the epitope of VHPAM-V16F4. The 
template for mutagenesis (GenScript) was the full-length human PDGFR cDNA inserted into the 
retroviral vector pLHDCX2 (22). The PDGFR mutants were termed Ala-scans and numbered from 
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. Two longer 
Ala-scans were generated combining Ala-scan1 and 2 (Ala-scan4) or Ala-scan1, 2 and 3 (Ala-
scan5). The five Ala-scans were individually transfected into PA317 cells (ATCC) with 
Lipofectamine to produce retroviral virions (23). Virus-containing medium was collected, 
concentrated (25,000 g, 90 minutes, 4°C) and used to infect F-/- cells (12) grown in DMEM with 8 
µg/ml polybrene (hexadimethrine bromide; Sigma-Aldrich) for 24 hours. Successfully infected cells 
were selected in histidine-free DMEM containing 5 mM histidinol (Sigma-Aldrich) (24). Mutated 
PDGFR expression was assessed by FACS using VHPAM-V16F4 and mab 1264 antibodies.   
 
Immunoenzymatic assays (ELISA)  
A recombinant receptor fused to a poly-Histidine tag (PDGFR-His) produced in-house (25) or 
commercial (amino acid Met 1-Glu 524, cod. 10556-H08H, Sino Biological Inc.) were immobilized 
[0.5 g/ml in 100 l of Hepes buffered saline (HBS), pH 7.2] onto 96-well Maxisorp ELISA plates 
(Nunc) overnight at 4°C. After 2 hours blocking at 37°C with 200 l of HBS containing 0.2% 
polyvinylpyrrolidone (Sigma-Aldrich) and washing with HBS/0.05% Tween 20, serum (1:100 in 
HBS, 100 l/well) was added overnight at 4°C. After extensive washing, HRP-conjugated anti-
human IgG (1:10.000, 100 l/well) (Jackson Immunoresearch) were added for 1 hour at 20°C. The 
reaction was developed with 100 l of tetramethylbenzidine (TMB, BioFX) for 10 minutes at room 
temperature, then stopped with 50 l of 0.5 M H2SO4. The optical density (O.D.) was measured at 
450 nm. In the peptide-based ELISA, 20 µg/ml of each peptide were immobilized onto 96-well 
plates and probed with 0.7 µg/ml of the indicated rHumaab. In the competitive ELISA, serum 
(1:100), VHPAM-V16F4 (0.7 µg/ml) or PDGF-BB (15 ng/ml) were pre-incubated with 25 g/ml of 
the indicated peptide (molar ratio peptide : PDGFR = 50:1) for 1 hour at 37°C. Alternatively, 
serum (1:100) was incubated with immobilized PDGFRα-His overnight at 4°C, before adding 
biotinylated VHPAM-V16F4 (ChromaLink Biotin Protein Labeling Kit Solulink, VWR 
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International) (100 ng/ml) for 2 hours at 37°C, followed by HRP-conjugated streptavidin (1:5.000) 
(Bio-Rad) for 1 hour at room temperature. 
 
Statistical Analysis  
Data are presented as means ± SEM or ± SD, as indicated, and were analyzed with one-way non-
parametric ANOVA analysis with Kruskal-Wallis and Dunn’s multiple comparison tests (peptide 
binding, direct and competitive ELISA) or two-tailed unpaired t test [confidence intervals (CI) 
95%] (functional, cell-based assays). Spearman's rank correlation coefficient for non-parametric 
data was calculated between the percentage of inhibition of VHPAM-V16F4 binding to PDGFRα-
His after incubation with sera and the percentage of binding inhibition of sera to PDGFRα after pre-
incubation with peptide 2. ROC curves were generated to determine the area under the curve (AUC) 
with its 95% CI. The optimal cut-off values were chosen according to the highest Youden index 
[sensitivity + (1 − specificity)], calculated using MedCalc12 software. GraphPad Prism 5 and 




Cloning of agonistic and nonagonistic anti-PDGFR autoantibodies from memory B cells of 
one SSc patient 
Immortalized memory B cells from one SSc patient (coded PAM) (9-11) were seeded in 96-well 
plates. Supernatants of ~2.000 wells were screened for expression of IgG selectively binding F but 
not F-/- fibroblasts (12), and inducing ROS. Three B cell cultures (namely, PAM13B8, PAM16F4 
and PAM17H8) contained PDGFR-binding IgG, of which PAM16F4 IgG induced ROS (Figure 
1A). RNA was extracted from these B cells, reverse-transcribed and amplified with primers 
designed to analyze the human IgG gene repertoire (13). PCR analysis of rearranged IgG genes 
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suggested the presence of a panel of VH and VL chains representative of most IgG subgroups 
(Figure 1B). However, subsequent sequencing revealed that most of these PCR products were 
similar, although not identical, at oligonucleotide level (Supplementary Figure 1), both within each 
single B cell culture and among the three cell cultures, indicating oligoclonal restriction. Indeed, 
PAM13B8, PAM16F4 and PAM17H8 cells shared a single VH chain amino acid sequence, 
designated VHPAM, and a VL chain, designated V13B8. Moreover, PAM 13B8 and 17H8 shared a 
V chain designated V13B8, whereas the repertoire of PAM16F4 included two additional VL 
chains (designated V16F4 and V16F4) (Figure 1B). The VHPAM cDNA and, alternatively, each 
of the four VLPAM cDNAs were cloned into an expression vector containing the human IgG1 
constant region (15) and transfected into CHO cells to produce four rHumaab, designated VHPAM-
V13B8, VHPAM-V13B8, VHPAM-V16F4 and VHPAM-V16F4. All rHumaab, except VHPAM-
V13B8, immunoprecipitated PDGFR from human fibroblast lysates (Figure 1C). VHPAM-
V16F4 and VHPAM-V16F4, but not VHPAM-V13B8 and VHPAM-V13B8, induced ROS 
production and ERK1/2 and AKT phosphorylation in vitro (Figure 1D). VHPAM-V16F4, but not 
VHPAM-V16F4, also induced Ha-Ras and type I collagen gene expression (Figure 1D). These data 
show that PDGFR binding and biological effects of these rHumaab can be dissociated, suggesting 
the presence of different PDGFR epitopes mediating such functions.  
 
Epitope mapping of human PDGFR 
To identify the PDGFR epitopes of the rHumaab, we used in silico molecular docking, i.e. a 
computer simulation of molecular interactions, as a starting model to predict the binding regions 
between homology-modeled monomeric human PDGFR and rHumaab Fab fragments or 
monomeric human PDGF-BB, the only PDGF isoform with resolved crystal structure. PDGF-BB 
was predicted to bind a discontinuous epitope encompassing four amino acid segments lying 
Page 10 of 33
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
11 
 
between the second and third Ig-like extracellular domains of PDGFR (Figure 2A, pink 
sequences), which is consistent with previous studies (26, 27). The agonistic rHumaab VHPAM-
V16F4 was predicted to bind to a discontinuous epitope within the second and third PDGFR 
extracellular domains, largely overlapping the PDGF-BB binding site (Figure 2B, blue sequences). 
Conversely, the predicted epitope of the non-agonistic rHumaab VHPAM-V13B8 encompassed a 
single linear amino acid sequence within the first PDGFR extracellular domain (Figure 2C, yellow 
sequence). Part of this sequence was shared by the larger, discontinuous epitope of the agonistic 
rHumaab VHPAM-V16F4, which comprised additional amino acid stretches in the first and second 
PDGFR domains (Figure 2D, green sequences). To experimentally validate these predictive data, 
we screened with PDGF-BB and the rHumaab a conformational PDGFR peptide library 
synthesized by Pepscan (28, 29). This approach highlighted a remarkable correspondence between 
the predicted (in silico) and the actual (in vitro) PDGFR epitopes bound by rHumaab and by 
PDGF-BB (Figure 2A-C, underlined sequences), except VHPAM-V16F4, which did not bind to any 
peptide, probably for incomplete representation of its conformational epitope in the library. 
Notably, the highest binding peaks of PDGF-BB and VHPAM-V16F4 occurred with looped 
peptides (data available upon request), corroborating the conformational nature of their PDGFR 
epitopes.  
To further validate the PDGFR epitope mapping, binding-competition experiments were 
performed on a Surface Plasmon Resonance (SPR) device where the PDGFR-His, immobilized 
and folded into a native-like conformation (25), was saturated with PDGF-BB or single rHumaab 
before adding each rHumaab. The resulting sensorgrams (Figure 2B-D, insets) showed that binding 
of VHPAM-V16F4 to PDGFR was completely prevented by PDGF-BB (Figure 2B
#
), but only 
partially prevented by VHPAM-V13B8 (Figure 2B
##
), likely for steric hindrance. VHPAM-V16F4 
slightly inhibited VHPAM-V16F4 binding (Figure 2B
###
). These data confirm that VHPAM-V16F4 
(inducing both ROS and type I collagen genes) recognizes an epitope overlapping the PDGF 
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binding site, but distinct from the epitopes of VHPAM-V13B8 (non-agonistic) and VHPAM-V16F4 
(inducing ROS, but not type I collagen genes). Conversely, binding of VHPAM-V13B8 and VHPAM-










), consistent with the minimal overlap between their epitopes. We conclude that there are three 
distinct PDGFR epitopes recognized by these antibodies. One epitope, largely shared by PDGF-
BB and by the ROS- and collagen-inducing VHPAM-V16F4, is conformational and discontinuous. 
The second epitope, bound by VHPAM-V16F4, inducing ROS but not collagen, is also 
conformational and discontinuous. The third epitope, bound by VHPAM-V13B8, is an apparently 
nonfunctional single peptide in the first extracellular domain of PDGFR.   
 
Specific PDGFR peptides interfere with binding and functions of VHPAM-V16F4 rHumaab 
and IgG from SSc patients 
The three peptides corresponding to the PDGFR sequences (Figure 2B, underlined sequences) 
composing the discontinuous epitope of VHPAM-V16F4, bound VHPAM-V16F4, but not VHPAM-
V13B8 or VHPAM-V13B8 (Figure 3A). Pre-incubation with any of these peptides significantly 
inhibited VHPAM-V16F4 binding to PDGFR (Figure 3B) and VHPAM-V16F4-mediated collagen 
gene induction (Figure 3C). Peptide 2 was the most effective inhibitor under these experimental 
conditions, it also significantly reduced PDGF binding (Figure 3B) and collagen gene induction and 
ROS production triggered by SSc IgG (Figure 3D). Peptide 1, but not peptide 3, inhibited SSc IgG-
induced ROS production (Figure 3D). The scrambled peptide 2 did not bind to VHPAM-V16F4, 
PDGF-BB or SSc IgG nor inhibited their agonistic effects (Figure 3A-D).   
 
Mutagenesis of the discontinuous epitope of the agonistic rHumaab VHPAM-V16F4  
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A limited Alanine scanning mutagenesis of the essential motifs (Figures 2B, blue sequences, and 
4A) composing the VHPAM-V16F4 epitope was performed. Binding to VHPAM-V16F4 was 
retained by Ala-scans 1, 2, 3 (Figure 4B); however, collagen gene stimulation by VHPAM-V16F4 
was observed with Ala-scans 1 and 3, but it was completely impaired by Ala-scan 2. (Figure 4C). 
This result is consistent with the finding that peptide 2 is the most effective inhibitor of VHPAM-
V16F4-induced collagen stimulation (Figure 3C) and indicates that the TFT amino acid motif is 
essential for collagen induction. Expression of Ala-scan 4, spanning motifs 1 and 2, or Ala-scan 5, 
spanning motifs 1, 2 and 3 (Figure 4A), impaired both VHPAM-V16F4 binding and collagen 
stimulation (Figure 4B,C). These results independently validate the PDGFR epitope mapping, 
highlighting the minimal extracellular PDGFR motif required for collagen gene stimulation. 
 
Detection of anti-PDGFR autoantibodies in the serum of SSc patients 
Three independent assays were established: 
A. Direct ELISA with PDGFR-His immobilized onto 96-well plates:  
sera from 70 consecutive patients with a definite diagnosis of SSc (8) (Supplementary Table 2), 
from 130 sex- and age-matched HC, and 26 consecutive patients with a definite diagnosis of 
primary Raynaud’s phenomenon (PRP) (30), were tested. Based on the optimal cut-off value 
determined by ROC curve analysis of SSc and HC O.D. values, 94.3% of SSc (66/70), 48.5% of 
HC (63/130) and 42.3% of PRP (11/26) sera were positive (P < 0.0001 between SSc and other 
groups) (Figure 5A). Similar results were obtained using a commercial PDGFR-His (data 
available upon request), ruling out any artificial binding of serum IgG to the PDGFR-His 
produced in-house. No sera showed non-specific binding to uncoated plates (not shown). 
B. Competitive ELISA between immobilized PDGFR-His and peptides covering the VHPAM-
V16F4 epitope :   
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to evaluate the presence of serum anti-PDGFR IgG recognizing the same epitope of the agonistic 
rHumaab VHPAM-V16F4, SSc and HC (n = 34 each) and PRP (n = 18) sera, chosen according to 
homogeneous O.D. frequency distributions in assay A., were incubated with peptide 2 (the most 
effective inhibitor of VHPAM-V16F4 and SSc IgG, Figure 3B-D) before binding to immobilized  
PDGFR. Based on the ROC curve optimal cut-off value, pre-incubation with peptide 2 
significantly inhibited PDGFR binding of 70.6% (24/34) of SSc sera, 11.7% (4/34) of HC and 
none (0/18) of PRP sera (P < 0.001 and P < 0.0001 between SSc and other groups, respectively) 
(Figure 5 B). Similar results were obtained repeating the assay with peptide 1, whereas peptide 3 
was less efficient, inhibiting binding of 50% (17/34) of SSc sera, 8.8% (3/34) of HC and none 
(0/18) of PRP sera (data available upon request). To confirm that inhibition was due to specific 
binding of peptide 2 to serum IgG , the assay was repeated using IgG purified from 8/24 positive 
SSc sera and from the 4 positive HC sera. While binding of SSc IgG was inhibited by peptide 2, HC 
IgG were no longer inhibited (data available upon request), suggesting the presence of serum 
components mediating binding of HC sera to peptide 2.  
C.  Competitive ELISA between sera and VHPAM-V16F4:   
to confirm that SSc sera contain autoantibodies similar to VHPAM-V16F4, the sera tested in B. 
were incubated onto immobilized PDGFRα-His before adding biotinylated VHPAM-V16F4. The 
24/34 SSc sera previously inhibited by peptide 2 significantly diminished VHPAM-V16F4 binding 
to PDGFRα. Only 2/34 (5.9%) HC and 2/18 (11.1%) PRP sera inhibited binding (Figure 5 C). 
Spearman’s rank correlation indicated that in the SSc group (P < 0.0001, r = 0.678), but not in the 
HC (P = 0.403, r = -0.147) and PRP (P = 0.668, r = -0.108) groups, the results of assays B. and C. 
were statistically associated.   
Finally, direct and competitive ELISA were performed with sera from 29 consecutive SLE patients 
(SLEDAI range: 2-20). PDGFRα binding distribution of SLE sera was comparable to those of HC 
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sera in assay A. and was not influenced by disease activity index or peptide 2 competition (Figure 5 
D).   
 
Comparison between ELISA and ROS assays in SSc patients and healthy controls 
IgG purified from 24/34 SSc sera analyzed by direct and competitive ELISA (Figure 5 A, B) and 
from four sera negative in direct ELISA (Figure 5A) were tested by ROS assay (3) (Table 1A). All 
sera positive by direct ELISA, including 16 samples positive and eight negative by competitive 
ELISA, contained ROS-inducing IgG, except serum #435, which was negative in competitive 
ELISA. Conversely, the four sera (#417, #433, #421, #424) negative in direct ELISA did not 
contain ROS-inducing IgG. The ROS-inducing activity of the seven samples negative in 
competitive ELISA (i.e., not containing antibodies with the same specificity of VHPAM-V16F4) 
was abolished by the PDGFR tyrosine kinase inhibitor AG1296, further suggesting that VHPAM-
V16F4-like IgG is not the only agonistic anti-PDGFR autoantibody species. HC IgG positive in 
direct ELISA did not induce ROS, except samples #31S and #356 which induced ROS through a 
PDGFR-independent mechanism, since ROS were unaffected by AG1296 (Table 1B).  
 
Discussion 
Human PDGFR has been implicated in a variety of diseases, including cancer, atherosclerosis and 
fibrosis (31-33); however, the PDGFR domains critical for disease pathogenesis are not 
completely defined. In vitro mutagenesis (26) and crystallographic (34) studies indicated that the 
amino acid residues involved in receptor binding by PDGF are located in the Ig-like extracellular 
domains 1, 2 and 3. The rHumaab generated from PDGFR-specific memory B cells of one SSc 
patient extend this information by identifying regions of the receptor transducing signals to NADPH 
oxidase (35, 36) and to collagen genes (37). These regions can largely overlap the canonical PDGF 
binding site (epitope of VHPAM-V16F4), or be distinct from it (epitope of VHPAM-V16F4). We 
suggest that these different PDGFR motifs, when stimulated, modulate local or/and long distance 
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propagation of signals of the activated receptor that selectively govern complex phenotypes such as 
fibrosis and oxidative stress (38). This study reconciles the controversial results concerning the 
existence of stimulatory anti-PDGFR antibodies in SSc (4, 5), demonstrating that: i. stimulatory and 
non-stimulatory anti-PDGFR autoantibodies may coexist in the same SSc patient; ii. stimulatory 
anti-PDGFR autoantibodies recognize specific conformational epitopes, which must be preserved 
in binding assays to discriminate agonistic from total antibodies, and can be mimicked by specific 
peptides; iii. stimulatory anti-PDGFR autoantibodies specific for these conformational epitopes 
are enriched in the serum of SSc patients. Moreover, the comparison between the ROS bioassay 
previously employed (3) and the peptide-based competitive ELISA described herein, using IgG 
purified from the same SSc and HC sera, although performed with a limited number of samples, 
indicated a remarkable concordance. The discordant results, i.e. the seven SSc samples testing 
negative by competitive ELISA but positive by ROS bioassay, can also be meaningfully interpreted. 
Indeed, these samples became unable to induce ROS in the presence of a specific PDGFR tyrosine 
kinase inhibitor, which demonstrates that they contain agonistic PDGFRα-specific antibodies. 
These antibodies differ from VHPAM-V16F4 since they are not inhibited by peptide 2. It is 
tempting to speculate that they are similar to VHPAM-Vλ16F4, the other agonistic antibody cloned 
from the SSc patient. The presence of different agonistic PDGFRα-specific antibodies, binding 
distinct epitopes, may account for the lower sensitivity of the competitive ELISA based on one 
epitope, compared to the ROS bioassay. Notably, the combined analysis of antibody binding and 
ROS production highlighted the existence of a subgroup of SSc patients without stimulatory anti-
PDGFR IgG. This group was not found in the previous small SSc cohort in which only ROS 
activity was measured (3). Non-stimulatory anti-PDGFRα antibodies have been identified by others 
in SSc and SLE patients and in HC (5, 6). Our data confirm these findings, and indicate that 
complete discrimination between nonagonistic and agonistic autoantibodies can be achieved only 
by combination of epitope-based binding assays and functional assays. Of note, IgG purified from 
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the two HC and PRP sera inhibiting binding of biotinylated VHPAM-V16F4 to PDGFR did not 
induce ROS (data available upon request). The assessment of the diagnostic relevance of 
stimulatory anti-PDGFRα antibodies, i.e. their efficacy in discriminating patients affected by early 
stage SSc from patients affected by related conditions such as PRP, will require the prospective 
screening of large cohorts of patients suspected for SSc (39) by optimized peptide-based assays. 
Moreover, the longitudinal analysis of agonistic anti-PDGFR antibodies during disease 
progression will indicate their potential usefulness as SSc biomarker (40). Notably, the 24 SSc 
patients testing positive at both competitive ELISAs had a more severe disease phenotype than the 
10 negative ones, but this observation must be confirmed in larger cohorts of patients. Finally, 
recent reports suggest that PDGFR inhibition may be a therapeutic option for SSc and other fibrotic 
conditions (41). Abrogation of VHPAM-Vk16F4-induced collagen gene overexpression by selective 
mutation of the minimal epitope motif and inhibition of SSc IgG-induced ROS production and 
collagen overexpression by use of peptides mimicking the epitope itself, further corroborate this 
possibility, hinting to promising new therapeutic strategies against SSc and other pathologic 
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Characterization of PAM 13B8, PAM 16F4, PAM 17H8 IgG. A, Flow cytometric analysis of IgG 
binding (white profile) to F or F-/- cells. Shaded profile is background fluorescence. ROS 
production was measured in F cells by DCFH-DA fluorescence and expressed as relative 
fluorescence units (RFU). Results represent the mean  SEM of three experiments (*P < 0.05). B, 
Subgroup specificity of PCR amplified IgG cDNA fragments identified in PAM 13B8, 16F4 and 
17H8 cells. VH or VL chain sequences with the same color encode for the same transcripts. The 
VH chain (blue) shared by PAM 13B8, 16F4 and 17H8 cell lines, was designated VHPAM. The VL 
sequences were classified according to the  or  subgroups and the PAM cell line in which they 
were first identified. C, PDGFR was immunoprecipitated (IP) from human fibroblasts with the 
four rHumaab and visualized by western blotting (WB) using an anti-PDGFR antibody. Anti-
PDGFR mab1264 was used as control. D, Levels of ROS, p-AKT, p-ERK1/2 and Ha-Ras and 
collagen induction in human fibroblasts treated with rHumaab or PDGF-BB. Histograms represent 
the mean RFU or collagen expression fold increase values ± SEM of three experiments performed 
in duplicate (*P < 0.05, **P < 0.01). 
 
Figure 2.  
Epitope mapping of human PDGFR. A-D (left panels), Molecular docking models of monomeric 
PDGF-BB or the indicated rHumaab Fab fragments bound to the extracellular region of monomeric 
PDGFR, encompassing the five Ig-like domains, labeled I-V from the N- to the C-terminus. 
Below each model, the amino acid sequence of the first three N-terminal extracellular domains of 
PDGFR is shown. Along this sequence, the amino acids composing the predicted PDGF-BB and 
rHumaab binding sites are highlighted by colors. The binding sites identified in the PDGFR 
peptide library are underlined. B-D (right panels), Binding curves [measured in arc/seconds (arcsec) 
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over time] of the specific rHumaab to PDGFR-His immobilized onto the biosensor chip, alone (no 









Figure 3.  
Specific PDGFR peptides interfere with binding and functions of the agonistic VHPAM-V16F4 
rHumaab and of IgG from  SSc sera. A, Binding of VHPAM-V16F4, VHPAM-V16F4 and VHPAM-
V13B8 to immobilized peptides 1, 2, 3. B, Binding of VHPAM-V16F4 or PDGF-BB to 
immobilized PDGFR-His with or without pre-incubation with peptides (molar ratio peptide: 
PDGFR = 50:1) (***P < 0.001). C, Collagen induction by VHPAM-V16F4 with or without pre-
incubation with peptides (molar ratio peptide:rHumaab = 100:1). Asterisks indicate the statistical 
significance of inhibition of Col1A1 and Col1A2 gene induction in human fibroblasts exposed to 
VHPAM-V16F4 pre-incubated with peptides (*P < 0.05, **P < 0.01). D, Equal amounts of pooled 
IgG purified from sera of six SSc patients or six HC subjects were used to induce collagen gene 
expression or ROS production with or without pre-incubation with peptides. Peptide 2 inhibits SSc 
IgG-induced Col1A1 and peptide 1 and 2 inhibit ROS production(*P < 0.05). Col1A1 mRNA 
expression or ROS production were increased by SSc IgG (P < 0.05), TGFβ (P < 0.0001) or PDGF-
BB (P < 0.05), but not by HC IgG. Histograms represent the mean  SEM of three independent 
experiments performed in duplicate. 
 
Figure 4. 
Mutagenesis of the discontinuous epitope of the agonistic VHPAM-V16F4 rHumaab. A, 
Visualization of the PDGFR conformational epitope of VHPAM-V16F4. Epitope surface amino 
acid residues composing the VHPAM-V16F4 binding site predicted by molecular docking  are 
highlighted and rendered as light blue sticks. The corresponding translucent Van der Waals surface 
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is superimposed to depict the VHPAM-V16F4 binding pocket. Secondary structures of PDGFR 
are displayed using the ribbon representation. The different sites of alanine mutations (Ala-scans) 
are emphasized by dotted squares. B, FACS analysis of cell surface PDGFR expressed by F and 
Ala-scan-expressing F-/- cells stained with VHPAM-V16F4 and mab 1264, binding to a different 
epitope of PDGFR extracellular domain. F-/- cells were used as negative control. C, Collagen 
gene induction measured by real-time qPCR. Mouse type I collagen mRNA levels in F, F-/- and 
Ala-scan-expressing cells exposed to VHPAM-V16F4, normalized to the mean values of 
endogenous Cyclophilin A. Histograms represent the mean relative expression fold increase ± SEM 
of three experiments performed in duplicate, calculated by the 2-ΔΔCt method. (*P < 0.05).  
 
Figure 5.  
Detection of serum anti-PDGFR autoantibodies. A, Direct ELISA of sera from SSc, HC and PRP 
subjects. The horizontal line indicates the median (***P < 0.0001). O.D. = 0.129 is the optimal cut-
off for PDGFR binding between positive and negative sera, determined by ROC curve of SSc 
versus HC [sensitivity = 94.4%, specificity = 51.5%, AUC = 0.801 with 95% CI = 0.793 to 0.854]. 
B, Peptide 2 inhibits SSc sera binding to PDGFR. Median percentage binding inhibition of SSc 
sera = 36.05 versus 21.2 in HC sera and 3.6 in PRP sera (**P < 0.001 between SSc and HC; ***P < 
0.0001 between SSc and PRP). Inhibition = 29.8% represents the optimal cut-off discriminating 
sera whose binding to PDGFR is significantly inhibited by peptide 2, determined by ROC curve  
(sensitivity = 70.6%, specificity = 88.2%, AUC = 0.764 with 95% CI = 0.645 to 0.858). C, Binding 
inhibition of VHPAM-V16F4 to PDGFRα by sera. Median percentage of VHPAM-V16F4 binding 
inhibition by SSc sera = 30.60 versus 11.65 by HC and 5.45 by PRP sera (***P < 0.0001). 
Inhibition = 26.1% is the optimal cut-off discriminating sera inhibiting from those weakly or not 
inhibiting VHPAM-V16F4 binding to PDGFRα, determined by ROC curve (sensitivity = 70.6; 
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specificity = 94.1; AUC = 0.760 with 95% CI = 0.641 to 0.856). D, Direct or competitive ELISA of 
SLE sera. Each dot corresponds to the mean O.D. of each sample, tested in triplicate.  
 
Table 1.  
Comparison between ELISA and ROS assays in SSc patients and HC subjects. Melon gel-purified 
IgG (200 µg/ml) from A, 24 SSc serum samples that had been subjected to both direct and 
competitive ELISA and 4 SSc serum samples testing negative to direct ELISA, and B, from 26 HC 
serum samples of which 24 positive and 2 negative in the anti-PDGFRα direct ELISA, were tested 
for their ability to induce ROS production in Fα cells. Red color indicates values over the cut-off 
and blue color indicates values under the cut-off. Binding: cut-off = 0.129 (O.D. column); % 
binding inhibition by peptide 2: cut-off = 29.8; ROS: cut-off = 0.4 (stimulation index, SI). SI = (S − 
C) ÷ (P − C), where S is the DCF fluorescence intensity of the test IgG, C is the DCF fluorescence 
intensity of a negative control obtained by culturing cells without IgG, and P is the DCF 
fluorescence intensity of a positive control obtained by incubating cells with PDGF (15 ng/ml for 
15 minutes). Samples able to induce ROS were tested in the presence of PDGFR inhibitor 
AG1296 (2 µM). 
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